EUVIMEDObjevte EUVIMED
StudienprotokollOpen access

Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study

Rajiv Kumar iD, Safia May Farry iD, Mark Ezegbogu iD, Glen Reid iD, Euan James Rodger iD, Ben Brockway iD, Aniruddha Chatterjee iD

JMIR Research Protocols · 2026-08-27 · 15 · e105338-e105338

DOI: 10.2196/105338 ↗

At a glance

Studienprotokoll in JMIR Research Protocols, published online on 2026-08-27. Written by Rajiv Kumar and 6 co-authors. Institution: Department of Pathology and Molecular Medicine, Faculty of Medicine - Dunedin, University of Otago, 58 Hanover Street, Hercus Building, Dunedin, 9016…. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Early Detection of Cancer, Biomarkers, Tumor. 71 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and continues to have poor survival outcomes, with most patients diagnosed at advanced stages of disease. In New Zealand, NSCLC contributes substantially to cancer inequities, with Māori communities experiencing disproportionately high incidence and mortality rates. Although low-dose computed tomography screening can improve early detection, major limitations remain, including false-positive findings, overdiagnosis, high infrastructure costs, and limited accessibility for rural and underserved populations. Liquid biopsy approaches using circulating tumor DNA (ctDNA), particularly DNA methylation profiling, have emerged as promising, minimally invasive strategies for improving cancer detection, treatment monitoring, and precision oncology.

Objective

This study aims to establish integrated genomic and epigenomic predictive and prognostic biomarkers using ctDNA, tumor tissue, and transcriptomic profiling to improve early detection, risk stratification, treatment selection and response prediction, and longitudinal monitoring, with particular emphasis on identifying molecular mechanisms associated with treatment resistance and disease progression.

Methods

This prospective observational translational biomarker study is being conducted through the University of Otago and associated respiratory and oncology services in New Zealand. The study will recruit participants with NSCLC (including squamous and nonsquamous subtypes), individuals referred to fast-track lung nodule assessment clinics, and nonmalignant respiratory controls. Serial peripheral blood sampling will be performed in selected participants at predefined clinical follow-up time points to evaluate treatment response and disease progression. The availability of formalin-fixed paraffin-embedded archival tissues will be recorded, but will not be mandatory for enrollment. Genome-scale DNA methylation profiling will be performed using cell-free reduced representation bisulfite sequencing (cfRRBS), while targeted genomic profiling and transcriptomic analyses will be conducted using targeted sequencing panels and RNA sequencing. Integrative bioinformatic analyses will be used to identify molecular biomarkers associated with early-stage disease, advanced disease, treatment response, and therapeutic resistance.

Results

Ethics approval for the study has been obtained from the New Zealand Health and Disability Ethics Committee (2022 EXP 12566). This study commenced in 2022, and recruitment and biospecimen collection are ongoing. The study aims to recruit approximately 450 participants, including patients with NSCLC, individuals referred through respiratory diagnostic pathways, and nonmalignant controls. As of July 31, 2026, 205 participants have been recruited, with recruitment continuing until the target sample size is reached. Molecular and data analyses are ongoing, with additional publications expected as the cohort matures.

Conclusions

This study will generate one of the first integrated genomic, epigenomic, and transcriptomic liquid biopsy datasets for NSCLC in New Zealand. The findings are expected to support the development of sensitive, accessible, and equitable blood-based biomarkers for NSCLC detection and treatment monitoring while also contributing to improved precision oncology approaches and reducing NSCLC inequities among Māori populations.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsEarly Detection of CancerBiomarkers, TumorEpigenomicsHumansProspective StudiesNew ZealandTranslational Research, BiomedicalDNA MethylationCirculating Tumor DNAObservational Studies as TopicEpigenesis, GeneticGene Expression ProfilingLiquid Biopsy

Author keywords

DNA methylationMāori healthRRBSbiomarkerscirculating tumor DNAearly detectionepigeneticsliquid biopsylung cancerreduced representation bisulfite sequencingtranscriptomicstreatment response

Substances

Biomarkers, TumorCirculating Tumor DNA

Authors and institutions

  • Department of Pathology and Molecular Medicine, Faculty of Medicine - Dunedin, University of Otago, 58 Hanover Street, Hercus Building, Dunedin, 9016, New Zealand, 64 210701558.
  • Department of Medicine, Faculty of Medicine - Dunedin, University of Otago, Dunedin, New Zealand.
  • Mercy Cancer Care, Mercy Hospital, Dunedin, New Zealand.
  • Te Whatu Ora - Southern, Health New Zealand, Dunedin, New Zealand.

ORCID profiles: Rajiv Kumar, Safia May Farry, Mark Ezegbogu, Glen Reid, Euan James Rodger, Ben Brockway, Aniruddha Chatterjee

Cite

APA

Kumar, R., Farry, S. M., Ezegbogu, M., Reid, G., Rodger, E. J., Brockway, B., & Chatterjee, A. (2026). Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study. JMIR Research Protocols, 15, e105338-e105338. https://doi.org/10.2196/105338

Vancouver

Kumar R, Farry SM, Ezegbogu M, Reid G, Rodger EJ, Brockway B, et al. Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study. JMIR Research Protocols. 2026;15:e105338-e105338. doi:10.2196/105338

BibTeX
@article{Kumar2026,
  author = {Kumar, Rajiv and Farry, Safia May and Ezegbogu, Mark and Reid, Glen and Rodger, Euan James and Brockway, Ben and Chatterjee, Aniruddha},
  title = {Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e105338--e105338},
  doi = {10.2196/105338}
}
Start for free →